CSF2 and neoplasm: The ONCOS-102 is a chimeric oncolytic adenovirus armed with human GM-CSF and Ad5/3 chimeric capsids, and it has shown promising anti-tumor effects through the upregulation of PD-L1 in a phase I clinical trial against solid tumors (NCT01598129) [10].